Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro

Abstract

Pituitary adenomas (PAs) are well known as a common intracranial benign tumor, and a portion of PAs are refractory to current therapeutic methods. ErbB receptors family signaling pathway regulates the expression of PAs activation associated gene. Inhibition of epidermal growth factor receptor (EGFR) can inhibit proliferation of PAs. Leucine-rich repeats and immunoglobulin-like domains protein 1 ( LRIG1), a negative mediated gene of ErbB receptors family, plays a role in many tumors. However, there are seldom researches about the functional role of LRIG1 in PAs. The aim of this study is to explore the potential effect of LRIG1 and its regulating mechanism in PAs. First, we investigated the role of LRIG1 in cell migration, invasion of PAs with transfected LRIG1 or control. Then, we explored its impact on cell proliferation and apoptosis of PAs in vivo. To study the regulating mechanism of LRIG1, we examined the expression of molecular factor of PI3K/AKT and Ras/Raf/ERK pathway using Western blotting in vitro and RT-PCR in vitro and in vivo. It was found that LRIG1 over-expression inhibited cell migration, invasion and proliferation, and promoted apoptosis of PAs in vivo and in vitro. Furthermore, LRIG1 suppressed the expression of signaling of PI3K/AKT and Ras/Raf/ERK pathways in PAs. LRIG1, as a negative mediated gene of tumor, can inhibit biological function of PAs via inhibiting PI3K/AKT and Ras/Raf/ERK pathways, and it might be a new target for gene therapy of PAs.

Keywords

LRIG1 / pituitary adenoma / biological function

References

[1] Di IevaA, RotondoF, SyroL V, et al. . Aggressive pituitary adenomas—diagnosis and emerging treatments. Nat Rev Endocrinol, 2014, 10(7): 423-435 PMID: 24821329

[2] MelmedS. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest, 2003, 112(11): 1603-1618 PMID: 14660734 PMCID: 281651

[3] GillamMP, MolitchME, LombardiG, et al. . Advances in the treatment of prolactinomas. Endocr Rev, 2006, 27(5): 485-534 PMID: 16705142

[4] Newell-PriceJ, BertagnaX, GrossmanA B, et al. . Cushing's syndrome. Lancet, 2006, 367(9522): 1605-1617 PMID: 16698415

[5] BakerNE, YuSY. The EGF receptor defines domains of cell cycle progression and survival to regulate cell number in the developing Drosophila eye. Cell, 2001, 104(5): 699-708 PMID: 11257224

[6] AnderssonU, GuoD, MalmerB, et al. . Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol, 2004, 108(2): 135-142 PMID: 15148612

[7] FukuokaH, CooperO, Ben-ShlomoA, et al. . EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest, 2011, 121(12): 4712-4721 PMID: 22105169 PMCID: 3226010

[8] OnguruO, ScheithauerBW, KovacsK, et al. . Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol, 2004, 17(7): 772-780 PMID: 15098012

[9] TheodoropoulouM, ArzbergerT, GrueblerY, et al. . Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol, 2004, 183(2): 385-394 PMID: 15531726

[10] VlotidesG, SiegelE, DonangeloI, et al. . Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res, 2008, 68(15): 6377-6386 PMID: 18676863 PMCID: 2497431

[11] FukuokaH, CooperO, MizutaniJ, et al. . HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol, 2011, 25(1): 92-103 PMID: 21106881

[12] GuoD, HolmlundC, HenrikssonR, et al. . The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics, 2004, 84(1): 157-165 PMID: 15203213

[13] HedmanH, NilssonJ, GuoD, et al. . Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?. Acta Oncol, 2002, 41(4): 352-354 PMID: 12234026

[14] GuoD, HanL, ShuK, et al. . Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line. J Huazhong Univ Sci Technolog Med Sci, 2007, 27(1): 91-94 PMID: 17393120

[15] YeF, GaoQ, XuT, et al. . Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol, 2009, 94(2): 183-194 PMID: 19300910

[16] ZhangH, YanQ, XuS, et al. . Association of expression of Leucine-rich repeats and immunoglobulin-like domains 2 gene with invasiveness of pituitary adenoma. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(4): 520-523 PMID: 21823015

[17] LaederichM B, Funes-DuranM, YenL, et al. . The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem, 2004, 279(45): 47050-47056 PMID: 15345710

[18] GurG, RubinC, KatzM, et al. . LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J, 2004, 23(16): 3270-3281 PMID: 15282549 PMCID: 514515

[19] StutzMA, ShattuckDL, LaederichMB, et al. . LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene, 2008, 27(43): 5741-5752 PMID: 18542056 PMCID: 3175812

[20] YokdangN, HatakeyamaJ, WaldJ H, et al. . LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells. Oncogene, 2016, 35: 1932-2947

[21] SheuJJ, LeeCC, HuaCH, et al. . LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling. Oncogene, 2014, 33(11): 1375-1384 PMID: 23624915

[22] LiuX, KanoM, ArakiT, et al. . ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. Endocrinology, 2015, 156(1): 71-79 PMID: 25375038

[23] CooperO, MamelakA, BannykhS, et al. . Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine, 2014, 46(2): 318-327 PMID: 24287797

[24] ZhangX, SongQ, WeiC, et al. . LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells. Cell Stress Chaperones, 2015, 20(4): 631-641 PMID: 25860915 PMCID: 4463919

[25] KouC, ZhouT, HanX, et al. . LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer. Biochem Biophys Res Commun, 2015, 464(2): 519-525 PMID: 26159916

[26] YangJA, LiuBH, ShaoLM, et al. . LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway. Int J Clin Exp Pathol, 2015, 8(4): 3580-3590 PMID: 26097540 PMCID: 4466927

[27] FaivreS, KroemerG, RaymondE. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov, 2006, 5(8): 671-688 PMID: 16883305

[28] ZhouJ, ZhiX, WangL, et al. . Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res, 2015, 34(1): 135 PMID: 26538117 PMCID: 4632266

[29] LiuJF, TsaoYT, HouCH. Amphiregulin enhances intercellular adhesion molecule-1 expression and promotes tumor metastasis in human osteosarcoma. Oncotarget, 2015, 6(38): 40880-40895 PMID: 26503469 PMCID: 4747375

[30] YangY, ShengM, HuangF, et al. . Downregulation of insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth. Pituitary, 2014, 17(6): 505-513 PMID: 24379119

[31] BruhnMA, PearsonRB, HannanRD, et al. . Second AKT: the rise of SGK in cancer signaling. Growth Factors, 2010, 28(6): 394-408 PMID: 20919962

[32] GaoJ, LiuX, YangF, et al. . By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis. Oncotarget, 2015, 6(29): 27187-27198 PMID: 26356670 PMCID: 4694982

[33] HuY, LiuHX, HeY, et al. . Transcriptome profiling and genome-wide DNA binding define the differential role of fenretinide and all-trans RA in regulating the death and survival of human hepatocellular carcinoma Huh7 cells. Biochem Pharmacol, 2013, 85(7): 1007-1017 PMID: 23396089

[34] HanT, XiangDM, SunW, et al. . PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol, 2015, 63(3): 651-660 PMID: 25865556